Business
First Tracks Biotherapeutics Announces First Quarter 2026 Financial Results and Provides Business Update
First Tracks launched April 20th with a two-year cash-runway to advance ANB033 through celiac disease and eosinophilic esophagitis Phase 1b data and plans to initiate Phase 2 trials across four indications SAN DIEGO, May 14, 2026 (GLOBE NEWSWIRE) -- First Tracks Biotherapeutics, Inc. (Nasdaq: TRAX), a clinical-stage biotechnology company advancing antibody therapeutics that modulate immune pathways implicated in autoimmune and inflammatory diseases, today reported financial results for the first
About this update from First Tracks Biotherapeutics, Inc.
[{"type":"image","alt":"First Tracks Biotherapeutics Inc","displaySize":"","headline":null,"caption":"First Tracks Biotherapeutics Inc","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":167,"url":"https://media.zenfs.com/en/globenewswire.com/d8c721c023473fafae31220ac137f711"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/.TAcovyaHiH6hkuhrt7WwA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIzNA--/https://media.zenfs.com/en/globenewswire.com/d8c721c023473fafae31220ac137f711","width":300,"height":167},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/.TAcovyaHiH6hkuhrt7WwA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIzNA--/https://media.zenfs.com/en/globenewswire.com/d8c721c023473fafae31220ac137f711","width":300,"height":167}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"First Tracks launched April 20th with a two-year cash-runway to advance ANB033 through celiac disease and eosinophilic esophagitis Phase 1b data and plans to initiate Phase 2 trials across four indications","length":205,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":205,"olType":false},{"type":"text","content":"SAN DIEGO, May 14, 2026 (GLOBE NEWSWIRE) -- First Tracks Biotherapeutics, Inc. (Nasdaq: TRAX), a clinical-stage biotechnology company advancing antibody therapeutics that modulate immune pathways implicated in autoimmune and inflammatory diseases, today reported financial results for the first quarter ended March 31, 2026, and provided a business update.","length":356,"tagName":"p"},{"type":"text","content":"“First Tracks Bio launched to advance a focused, high-value immunology portfolio that can create meaningful impact and a future where autoimmune diseases no longer define a patient’s life,” said Daniel Faga, president and chief executive officer. “We remain committed to executing with speed, rigor and financial discipline with a focus on ANB033, a CD122 antagonist, as we prepare for multiple clinical readouts in celiac disease and eosinophilic esophagitis. Additionally, we completed a productive End-of-Phase 2 meeting for rosnilimab with FDA, and we are assessing ROE-maximizing strategic options for this asset, including potential for development in rheumatoid arthritis and other indications.”","length":702,"tagName":"p"},{"type":"text","content":"ANB033 (CD122 antagonist)","length":25,"tagName":"p"},{"type":"list...